Live Better
& Longer

Help Therapeutics is a clinical stage biotech company based in Nanjing, China. Founded in 2016, Help Therapeutics is the first company in China to use induced-pluripotent stem cells (iPSC) and mesenchymal stem cell (MSC) technology to develop a new generation of universal cell therapy products to treat clinically incurable degenerative diseases. The Company's most advanced indications for its iPSC technology are heart failure and dilated cardiomyopathy with earlier stage products for Parkinson's Disease and Age-related Macular Degeneration.

We have accumulated strong expertise and valuable real-world experience in multi-regional clinical trials centers in order to forward the development of human-iPSC-derived cardiomyocytes for heart failure filed by National Health Commission of China. We are committed to driving and empowering affordable innovation by our world-wide breakthrough in the development of cell manufacturing and quality control called Help Cell-foundry, which is composed of three major functional platforms combing machine learning and high-performing computing optimization.

At Help Therapeutics, we believe that the best way to deliver safe, effective and affordable cell therapy products is to provide superior development and manufacturing technologies, value and support at every stage of the journey to bring the next generation advanced therapies to patients in deed.

Our Road


Help Therapeutics was founded by Dr. Jiaxian WANG


The iPS Cell Model Bank for Intractable Diseases was established


Our strategy was made for developing iPSC-derived cardiomyocytes for heart failure indication


The First in Human study of HiCM-188 was initiated


1-year follow-up study of HiCM -188 was reported by Nature

The first certification of iPSC-drived cardiomyocytes was issued by China National Institutes For Food and Drug Control (NIFDC)


Help Therapeutics raised hundreds of millions (CNY) / Series C

The first clinical approval of iPSC based cell therapy was filed by National Health Commission in China

HELP Cell-foundry, a cutting edge automatic facility for cell production and QC, was launched complying with US & Sino GMP standards


Joint labs with University of Macau and Oujiang Laboratory were established

HiCM -188’s IND application was submitted to CDE

Our team
Dr.Eugene, J. WANG
Founder & CEO, Help Therapeutics Co., Ltd.

Achievements of
Stem Cell Innovation


Two grants of the State National Key R&D Programs
2022: Vascular reconstraction and its application in ischemic heart failure based on stem cell and biomaterial engineering
2017: Stem cell therapy for heart failure


The Technology & Innovation Exhibition of China 13th Five-Year Plan (2021)
Cardio-regeneration cell therapy
Integrated multi-scale & automatic cell-foundry platform


Progress of HiCM-188
The first domestic iPSC-driven clinical trial filed by National Health Commission of China: MR-32-21-014649 IND approval in Jan 2023
Collaborator: Prof. Dongjin WANG, Nanjing Drum Tower Hospital


The Project of iPSC Preservation Study collaborated with S&T institute of China National Health Commission
The standardized construction and application of human iPSC-derived cell model bank

We Are Here



Building 1, Life Science and Technology Town, No.568 Longmian Avenue, Jiangning District, Nanjing, China

San Francisco

North America Office

1633 Old Bayshore Hwy, Burlingame, CA 94010


Beijing Office

51A, Jingyuan Art Center, No.3 Guangqu Road, Chaoyang District, Beijing, China


Help Therapeutics Research Center

Creative Valley, No.1889 Huandao East Road, Hengqin New District, Zhuhai, China